These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 35292660)
1. MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40/CD40L system in osteosarcoma. Jiang K; Zhang Q; Fan Y; Li J; Zhang J; Wang W; Fan J; Guo Y; Liu S; Hao D; Wang Y; Wang L; Shan L Cell Death Discov; 2022 Mar; 8(1):117. PubMed ID: 35292660 [TBL] [Abstract][Full Text] [Related]
2. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370 [TBL] [Abstract][Full Text] [Related]
4. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells. Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184 [TBL] [Abstract][Full Text] [Related]
5. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model. Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948 [TBL] [Abstract][Full Text] [Related]
6. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy. Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667 [TBL] [Abstract][Full Text] [Related]
7. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG Front Immunol; 2020; 11():620166. PubMed ID: 33584714 [TBL] [Abstract][Full Text] [Related]
9. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma. Yang H; Zhao L; Zhang Y; Li FF Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887 [TBL] [Abstract][Full Text] [Related]
10. Specific inhibition of PI3Kδ/γ enhances the efficacy of anti-PD1 against osteosarcoma cancer. Shi X; Li X; Wang H; Yu Z; Zhu Y; Gao Y J Bone Oncol; 2019 Jun; 16():100206. PubMed ID: 31334002 [TBL] [Abstract][Full Text] [Related]
11. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349 [TBL] [Abstract][Full Text] [Related]
16. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME). Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604 [TBL] [Abstract][Full Text] [Related]
17. SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy. Jiang K; Li J; Zhang J; Wang L; Zhang Q; Ge J; Guo Y; Wang B; Huang Y; Yang T; Hao D; Shan L Int Immunopharmacol; 2019 Oct; 75():105818. PubMed ID: 31437795 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma. Kawano M; Itonaga I; Iwasaki T; Tsumura H Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864 [TBL] [Abstract][Full Text] [Related]
19. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy. Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991 [No Abstract] [Full Text] [Related]
20. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. Isaacs J; Anders C; McArthur H; Force J Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]